Zoetis Inc. (ZTS)

Market Cap	77.05B
Revenue (ttm)	8.73B
Net Income (ttm)	2.39B
Shares Out	456.30M
EPS (ttm)	5.19
PE Ratio	32.54
Forward PE	28.20
Dividend	$1.73 (1.02%)
Ex-Dividend Date	Apr 18, 2024

Volume	2,042,854
Open	169.81
Previous Close	167.91
Day's Range	168.63 - 170.20
52-Week Range	144.80 - 201.92
Beta	0.86
Analysts	Strong Buy
Price Target	211.57 (+25.29%)
Earnings Date	May 2, 2024

About ZTS

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 1, 2013
• Employees: 14,100
• Stock Exchange: NYSE
• Ticker Symbol: ZTS

Financial Performance

In 2023, Zoetis's revenue was $8.54 billion, an increase of 5.74% compared to the previous year's $8.08 billion. Earnings were $2.34 billion, an increase of 10.88%.

Analyst Forecast

According to 7 analysts, the average rating for ZTS stock is "Strong Buy." The 12-month stock price forecast is $211.57, which is an increase of 25.29% from the latest price.

Price Target

$211.57

(25.29% upside)

Analyst Consensus: Strong Buy